Cutler Group’s Benitec Biopharma BNTC Stock Holding History

Cutler Group’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-59	Closed	–	–	3804
2023 Q2	$0	Hold	59	–	–	﹤0.01%	3594
2023 Q1	$0	Hold	59	–	–	﹤0.01%	3832
2022 Q4	$0	Hold	59	–	–	﹤0.01%	4422
2022 Q3	$0	Buy	+59	New	+$750	﹤0.01%	4925

Other funds holding BNTC

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Cutler Group's BNTC Position: Q3 2023 in Review

Cutler Group sold out of Benitec Biopharma (BNTC) in Q3 2023, closing a stake of 59 shares.

Cutler Group first reported a position in BNTC in Q3 2022 and held it in 4 quarters. The position peaked at $0 in Q2 2023. 12 funds tracked by Wall St. Rank hold BNTC as of Q3 2023.

Cutler Group reported no remaining Benitec Biopharma position as of Q3 2023 after selling out during the quarter.
Cutler Group sold 59 Benitec Biopharma shares in Q3 2023.
Cutler Group first reported a position in Benitec Biopharma in Q3 2022 and held it in 4 quarters.
Cutler Group's Benitec Biopharma position peaked at $0 in Q2 2023.
12 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.